drugset / Trial / NCT02563548
A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors
Parallel-groupOpen-labelTreatment
Summary
This is a Phase 1b study evaluating a combination of PEGPH20 and pembrolizumab in hyaluronan-high (HA-high) participants with relapsed/refractory non-small cell lung cancer (NSCLC) and HA-high participants with relapsed/refractory gastric adenocarcinoma (GAC).
Timeline
- Start
- 2015-10-22
- Primary completion
- 2019-03-26
- Completion
- 2019-03-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegvorhyaluronidase Alfa | Protein / enzyme biologic | 1.6 ug/kg | Intravenous |
| Subject | Pegvorhyaluronidase Alfa | Protein / enzyme biologic | 2.2 ug/kg | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |